Cargando…
Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
A severe form of respiratory disease – COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350468/ https://www.ncbi.nlm.nih.gov/pubmed/32317431 http://dx.doi.org/10.4103/ijo.IJO_639_20 |
_version_ | 1783557275131052032 |
---|---|
author | Shetty, Rohit Ghosh, Arkasubhra Honavar, Santosh G Khamar, Pooja Sethu, Swaminathan |
author_facet | Shetty, Rohit Ghosh, Arkasubhra Honavar, Santosh G Khamar, Pooja Sethu, Swaminathan |
author_sort | Shetty, Rohit |
collection | PubMed |
description | A severe form of respiratory disease – COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed. |
format | Online Article Text |
id | pubmed-7350468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-73504682020-07-15 Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future Shetty, Rohit Ghosh, Arkasubhra Honavar, Santosh G Khamar, Pooja Sethu, Swaminathan Indian J Ophthalmol Review Article A severe form of respiratory disease – COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed. Wolters Kluwer - Medknow 2020-05 2020-03-28 /pmc/articles/PMC7350468/ /pubmed/32317431 http://dx.doi.org/10.4103/ijo.IJO_639_20 Text en Copyright: © 2020 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Shetty, Rohit Ghosh, Arkasubhra Honavar, Santosh G Khamar, Pooja Sethu, Swaminathan Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title_full | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title_fullStr | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title_full_unstemmed | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title_short | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
title_sort | therapeutic opportunities to manage covid-19/sars-cov-2 infection: present and future |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350468/ https://www.ncbi.nlm.nih.gov/pubmed/32317431 http://dx.doi.org/10.4103/ijo.IJO_639_20 |
work_keys_str_mv | AT shettyrohit therapeuticopportunitiestomanagecovid19sarscov2infectionpresentandfuture AT ghosharkasubhra therapeuticopportunitiestomanagecovid19sarscov2infectionpresentandfuture AT honavarsantoshg therapeuticopportunitiestomanagecovid19sarscov2infectionpresentandfuture AT khamarpooja therapeuticopportunitiestomanagecovid19sarscov2infectionpresentandfuture AT sethuswaminathan therapeuticopportunitiestomanagecovid19sarscov2infectionpresentandfuture |